TETmedical

TETmedical, Inc. (Tethered Enzyme Technologies) is a clinical-stage nanomedicine diagnostics company spun out of Cornell University research, with labs at the Cornell Business & Technology Park in Ithaca, NY and an administrative office in Fair Haven, NJ. Its platform is a patented 'TET nanobot' — thousands of enzymes tethered to a nanoparticle — that performs chemical operations orders of magnitude faster than conventional antibody assays. Its lead product, NSE-FAST, is a rapid blood test to aid diagnosis of acute ischemic stroke, and received FDA Breakthrough Device Designation in June 2026. The platform is backed by more than $6M of NIH-funded research plus $2.8M in government grants, and the company was co-founded by serial medtech entrepreneur David Fischell with Cornell scientists Alex Travis and Roy Cohen.

Tethering thousands of enzymes to a single nanoparticle produces signal amplification far faster than antibody-based assays, which is what makes a rapid point-of-care blood test for acute stroke feasible where existing workflows miss roughly 17% of ischemic strokes (up to 42% of atypical presentations).